Copyright
©The Author(s) 2021.
World J Psychiatr. Sep 19, 2021; 11(9): 543-552
Published online Sep 19, 2021. doi: 10.5498/wjp.v11.i9.543
Published online Sep 19, 2021. doi: 10.5498/wjp.v11.i9.543
Table 2 Pharmacological options in the treatment of opioid use disorders
| Drug | Onset of action, duration | Route of administration | Clinical use |
| Opioid antagonists | |||
| Naloxone | Few minutes | i.v., nasal (spray) | Opioid overdose |
| Naltrexone | Daily | Oral | Abstinence |
| Naltrexone (depot) | One month | i.m. | Abstinence |
| Partial agonists | |||
| Buprenorphine | Daily | Sublingual | Maintenance |
| Buvidal | Weekly, monthly | Subcutaneous | Maintenance |
| RB_6000 (sublocade) | Monthly | Subcutaneous | Maintenance |
| Probuphine | 6 mo | Implant | Maintenance |
| Full agonists | |||
| Methadone | Daily | Oral | Maintenance |
| Heroin | Hours | i.v. | Maintenance |
| Morphine sulfate (retarded) | Daily | Oral | Maintenance |
| Morphine sulfate | Daily | Oral | Maintenance |
- Citation: Soyka M, Franke AG. Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations. World J Psychiatr 2021; 11(9): 543-552
- URL: https://www.wjgnet.com/2220-3206/full/v11/i9/543.htm
- DOI: https://dx.doi.org/10.5498/wjp.v11.i9.543